Database Commons

a catalog of biological databases

e.g., animal; RNA; Methylation; China

Database information

IARC TP53 Database (IARC TP53 Database)

General information

Description: The IARC TP53 Database compiles various types of data and information on human TP53 gene variations related to cancer. Data are compiled from the peer-reviewed literature and from generalist databases
Year founded: 2016
Last update: 2016
Version: R18
Accessibility:
Manual:
Accessible
Real time : Checking...
Country/Region: France
Data type:
DNA
Data object:
Database category:
Major organism:
Keywords:

Contact information

University/Institution: International Agency for Research on Cancer
Address: IARC, 150 Cours Albert Thomas, 69372 Lyon CEDEX 08, France
City:
Province/State:
Country/Region: France
Contact name (PI/Team): Magali Olivier
Contact email (PI/Helpdesk): olivierm@iarc.fr

Related Database

Record metadata

Created on: 2018-01-27
Curated by:
Fatima Batool [2018-04-18]

Ranking

All databases:
225/4516 (95.04%)
Gene genome and annotation:
86/1203 (92.934%)
Genotype phenotype and variation:
26/603 (95.854%)
Health and medicine:
45/904 (95.133%)
225
Total Rank
126
Citations
31.5
z-index

Community reviews

Not Rated
Data quality & quantity:
Content organization & presentation
System accessibility & reliability:

Word cloud

Publications

28499267
A novel germline TP53 mutation p.Pro190Arg detected in a patient with lung and bilateral breast cancers. [PMID: 28499267]
KrzeĊ›niak M, Butkiewicz D, Rachtan J, Matuszczyk I, Grzybowska E, Rusin M.

PURPOSE: Li-Fraumeni syndrome (LFS) is a rare genetic disease with strong predispositions to multiple early-onset neoplasms, mostly sarcomas, breast cancers, brain tumors and adrenocortical carcinomas (LFS core cancers). In most LFS families the germline mutations of TP53 tumor suppressor gene were found. Lung cancer does not belong to the core cancers of LFS, however its higher incidence is observed in families with TP53 mutations. Our aim was to search for TP53 mutations in female lung cancer patients whose clinico-demographic characteristics suggested a probable genetic predisposition to the disease.
MATERIALS AND METHODS: The coding region of TP53 from blood DNA was sequenced using Sanger method. The functioning of detected mutation was tested by luciferase reporter assay.
RESULTS: We found a nucleotide substitution c.569C>G, p.Pro190Arg, which was not described in the TP53 germline mutation database (http://p53.iarc.fr/TP53GermlineMutations.aspx). The mutation destroys the ability of p53 to transactivate BAX promoter and significantly reduces transactivation potential of p53 toward the promoter of MDM2 gen.
CONCLUSION: We identified novel germline mutation of TP53.

Adv Med Sci. 2017:62(2) | 1 Citations (from Europe PMC, 2020-01-18)
27328919
TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. [PMID: 27328919]
Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J, Olivier M.

TP53 gene mutations are one of the most frequent somatic events in cancer. The IARC TP53 Database (http://p53.iarc.fr) is a popular resource that compiles occurrence and phenotype data on TP53 germline and somatic variations linked to human cancer. The deluge of data coming from cancer genomic studies generates new data on TP53 variations and attracts a growing number of database users for the interpretation of TP53 variants. Here, we present the current contents and functionalities of the IARC TP53 Database and perform a systematic analysis of TP53 somatic mutation data extracted from this database and from genomic data repositories. This analysis showed that IARC has more TP53 somatic mutation data than genomic repositories (29,000 vs. 4,000). However, the more complete screening achieved by genomic studies highlighted some overlooked facts about TP53 mutations, such as the presence of a significant number of mutations occurring outside the DNA-binding domain in specific cancer types. We also provide an update on TP53 inherited variants including the ones that should be considered as neutral frequent variations. We thus provide an update of current knowledge on TP53 variations in human cancer as well as inform users on the efficient use of the IARC TP53 Database.

Hum Mutat. 2016:37(9) | 125 Citations (from Europe PMC, 2020-01-18)